IL2 and neoplasm: Targeting HDAC1/2 inhibits the binding of CoREST with IL-2 and the IFN-γ promoter, thereby promoting their expression, inhibiting the function of Treg, and enhancing anti-tumor immunity (Xiong et al., 2020).